Blood fatty acids in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review.

Blood fatty acids in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review. Ageing Res Rev. 2020 Mar 16;:101043 Authors: Hosseini M, Poljak A, Braidy N, Crawford J, Sachdev P Abstract Plasma fatty acids have been reported to be dysregulated in mild cognitive impairment (MCI) and Alzheimer's disease (AD), though outcomes are not always consistent, and subject numbers often small. Our aim was to use a meta-analysis and systematic review approach to identify if plasma fatty acid dysregulation would be observed in case control studies of AD and MCI. Six databases were searched for studies reporting quantified levels of fatty acids in MCI and/or AD individuals, relative to cognitively normal controls. Docosahexaenoic (DHA) and vaccenic acids were significantly lower and higher respectively in MCI relative to controls. Total fatty acids were 27.2% lower in AD relative to controls, and this was reflected almost uniformly in all specific fatty acids in AD. Changes to plasma/serum fatty acids were identified in both MCI and AD relative to age and gender matched controls. Differences were greatest in AD, in both total number of fatty acids significantly altered, and the degree of change. Docosahexaenoic acid was lower in both MCI and AD, suggesting that it may be a driver of pathology. PMID: 32194194 [PubMed - as supplied by publisher]
Source: Ageing Research Reviews - Category: Genetics & Stem Cells Authors: Tags: Ageing Res Rev Source Type: research

Related Links:

Publication date: Available online 29 May 2020Source: Pharmacology Biochemistry and BehaviorAuthor(s): Noura El Adle Khalaf, Farida Mohamed El Banna, Mona Younis Youssef, Youssef Mohammed Mosaad, Mohamed-Hesham Yousry Daba, Rehab Hamdy Ashour
Source: Pharmacology Biochemistry and Behavior - Category: Biochemistry Source Type: research
Flortaucipir F18 (Tauvid) for use with PET imaging helps estimate the density and distribution of tau pathology in adults with cognitive impairment who are being evaluated for Alzheimer ’ s disease.FDA Approvals
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Psychiatry News Alert Source Type: news
Condition:   Agitation in Patients With Dementia of the Alzheimer's Type Interventions:   Drug: AVP-786;   Drug: Placebo Sponsor:   Avanir Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The antidepressant bupropion was no better than placebo in reducing apathy in nondepressed patients with Alzheimer-type dementia in a randomized controlled trial.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Psychiatry News Source Type: news
A facile biosensor for Aβ40O based on fluorescence quenching of prussian blue nanoparticles. Talanta. 2020 Aug 15;216:120930 Authors: Chen W, Gao G, Jin Y, Deng C Abstract Amyloid β peptide oligomeFrs (AβOs) have been proved to be crucial biomarkers of Alzheimer's disease (AD). To explore an applicable method for the determination of AβOs is significant for the early AD diagnosis. Prussian blue nanoparticles (PBNPs), as one excellent nanomaterials, have the advantages of good stability, favorable biocompatibility, low cost, easy preparation and controllable shape. PBNPs was found t...
Source: Talanta - Category: Chemistry Authors: Tags: Talanta Source Type: research
A fair amount of effort is presently put towards the exploration of supplements derived from vitamin B3 compounds (nicotinamide, niacin, nicotinamide riboside) that act as precursors to enable the manufacture of nicotinamide adenine dinucleotide (NAD). NAD is an important component in mitochondrial activity, and levels decline with age. Some portion of the loss of mitochondrial function, implicated in the progression of many age-related conditions, is due to NAD insufficiency. There is a rich history of the use of high doses of vitamin B3 as an intervention, most of it predating modern understanding of the role of NAD in m...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
The increasing utilization of cerebrospinal fluid (CSF) in early detection of Alzheimer’s disease (AD) is attributed to the change of Amyloid-$beta$ proteins. Since, the brain is suspended in CSF, changes of Amyloid-$beta$ proteins in CSF reflect a pathophysiological variation of the brain due to AD. However, the correlation between Amyloid-$beta$ proteins and the dielectric properties (DPs) of CSF is still an open question. This paper reports the characterized DPs of CSF collected from canines using lumbar punctures. The CSF samples from canines show a strong correlation with respect to human in terms of the loss ta...
Source: IEEE Transactions on Biomedical Circuits and Systems - Category: Biomedical Engineering Source Type: research
The leukemia drug nilotinib, which shows promise in reducing the effects of Alzheimer's disease, is safe and has minimal side effects when used at low doses, according to a small clinical trial published Friday.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
(Lund University) Toxic versions of the protein tau are believed to cause death of neurons of the brain in Alzheimer's disease. A new study published in Nature Communications shows that the spread of toxic tau in the human brain in elderly individuals may occur via connected neurons. The researchers could see that beta-amyloid facilitates the spread of toxic tau.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Publication date: Available online 28 May 2020Source: Life SciencesAuthor(s): Partow Mirzaee Saffari, Sakineh Alijanpour, Nasrin Takzaree, Mousa Sahebgharani, Shahroo Etemad-Moghadam, Farshid Noorbakhsh, Alireza Partoazar
Source: Life Sciences - Category: Biology Source Type: research
More News: Alzheimer's | Databases & Libraries | Genetics | Pathology | Study